Astellas

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated

E_DEPRECATED Error in file �functions_general.php� at line 186: Function utf8_encode() is deprecated

Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyoâ€based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisationâ€™s focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellasâ€™ presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.

Keywords:

Date	News
2018-02-16	Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity
2018-02-14	Astellas Partners with Discovery Communications for its Global Branding Campaign
2018-02-14	Astellas Acquires Universal Cells, Inc.
2018-02-08	Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequat...
2018-02-06	Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in...
2018-02-05	Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees (pdf 200KB)
2018-02-05	Astellas Announces Personnel Changes and Organizational Changes (pdf 305KB)
2018-01-31	Astellas Appoints Kenji Yasukawa as President and CEO
2018-01-31	Astellas Announces Transition to a Company with an Audit & Supervisory Committee (pdf 242KB)
2018-01-31	Astellas Announces Acquisition of Own Shares (pdf 119KB)

Date

News

2018-02-16

Astellas Launches Global Campaign in Collaboration with CNN as Part of Global Corporate Brand Activity

2018-02-14

Astellas Partners with Discovery Communications for its Global Branding Campaign

2018-02-14

Astellas Acquires Universal Cells, Inc.

2018-02-08

Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequat...

2018-02-06

Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in...